Boletin 66 - Segundo Cuatrimestre 2023



Contenido destacado

Se ha publicado un resumen de evidencia

y un articulo de opinión



CAT 's

Nuevas Evidencias

Ahlberg R, Garcia-Argibay M, Taylor M, et al. 2023. Prevalence of sleep disorder diagnoses and sleep medication prescriptions in individuals with ADHD across the lifespan: a Swedish nationwide register-based study. BMJ Ment Health; 26:e300809.

Carr S, Hudson G, Amson N, et al. 2023. Service users’ experiences of social and psychological avoidable harm in mental health social care in England: Findings of a scoping review. The British Journal of Social Work, Volume 53, Issue 3, April 2023, Pages 1303–1324,

Degenhardt L, Clark B, Macpherson G, et al. 2023. Buprenorphine versus methadone for the treatment of opioid dependence: a systematic review and meta-analysis of randomised and observational studies. The Lancet Psychiatry. Volume 10, Issue 6, P386-402, June 2023. 

Fazel M, Soneson E, Sellars E. et al. 2023. Partnerships at the Interface of Education and Mental Health Services: The Utilisation and Acceptability of the Provision of Specialist Liaison and Teacher Skills Training. Int. J. Environ. Res. Public Health 20, 4066.

Fazel S, Vazquez-Montes MDLA, Molero Y, et al. 2023. Risk of death by suicide following self-harm presentations to healthcare: development and validation of a multivariable clinical prediction rule (OxSATS) BMJ Ment Health;26:e300673. 

Freeman D, Rosebrock L, Waite F, et al. 2023. Virtual reality (VR) therapy for patients with psychosis: Satisfaction and side effects. Psychological Medicine, 53(10), 4373-4384. doi:10.1017/S0033291722001167

Macdonald O, Green A, Walker A, et al. 2023. Impact of the COVID-19 pandemic on antipsychotic prescribing in individuals with autism, dementia, learning disability, serious mental illness or living in a care home: a federated analysis of 59 million patients’ primary care records in situ using OpenSAFELY. BMJ Ment Health;26:e300775. 

Meisinger C, Freuer D. 2023. Understanding the causal relationships of attention-deficit/hyperactivity disorder with mental disorders and suicide attempt: a network Mendelian randomisation study. BMJ Ment Health; 26:e300642.

Morales-Muñoz I, Mallikarjun PK, Chandan JS, et al. 2023. Impact of anxiety and depression across childhood and adolescence on adverse outcomes in young adulthood: a UK birth cohort study. The British Journal of Psychiatry, 222(5), 212-220. 

NICE. 2023. Alcohol-use disorders: diagnosis and management. Quality standard [QS11] Published: 24 August 2011 Last updated: 06 July 2023

NICE. 2023. Depression in adults. Quality standard [QS8] Published: 29 March 2011 Last updated: 29 June 2023 

NICE. 2023. Esketamine for treating major depressive disorder in adults at imminent risk of suicide (terminated appraisal). Technology appraisal [TA899]. Published: 06 June 2023

NICE. 2023. Guided self-help digital cognitive behavioural therapy for children and young people with mild to moderate symptoms of anxiety or low mood: early value assessment

Health technology evaluation. Reference number:HTE3 Published: 08 February 2023. Last updated:  05 September 2023

Paljärvi T, Herttua K, Taipale H, et al. 2023. Cause-specific excess mortality after first diagnosis of bipolar disorder: population-based cohort study. BMJ Ment Health; 26:e300700. 

Raison CL, Sanacora G, Woolley J, et al. 2023. Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial. JAMA. Sep 5;330(9):843-853. doi: 10.1001/jama.2023.14530.

Zarbo C, Rota M, Calza S, DiAPAson Collaborators, et al. 2023. Ecological monitoring of physical activity, emotions and daily life activities in schizophrenia: the DiAPAson study. BMJ Ment Health; 26:e300836.